Bangkok--Apr 18--PR & Associates
The acquisition will allow Pfizer to deliver a broader group of medicines and leverage its leadership on all fronts to provide enhanced support to the Thai medical community
Pfizer sees increased contribution to local communities to help improve public health
Pfizer International Corp. of Thailand began combining Pharmacia Thailand operations into its business, following final clearance by the U.S. Federal Trade Commission of the parent companies' proposal to merge their businesses globally.
Pfizer Thailand's parent, Pfizer Inc., is based in New York, and is the world's largest research-based pharmaceutical company. The combination with Pharmacia Corp., based in Peapack, New Jersey, brings together two of the world's fastest-growing and most innovative companies. It further expands Pfizer's global leadership, its offering of medicines, and its research and development capacity. As a combined company, Pfizer will also significantly expand its consumer health care brands and establish its animal health business as No. 1 in the world.
Pfizer also ranks as the No.1 research-based multinational pharmaceutical company in Thailand, where it has continuously operated for 45 years. The combination with Pharmacia will further increase Pfizer's leading position and increase its size by about 40% in terms of sales.
The combined pharmaceutical operations in Thailand will be headed by Amal Naj, the current Country Manager of Pfizer Thailand.
"As our Chairman and Chief Executive Officer Hank McKinnell has said, as a single combined company Pfizer will be helping more patients than any other pharmaceutical company has ever done before," said Mr. Naj, the Country Manager of Pfizer Thailand. "That is true for Thailand as well. We will be offering a broader range of drugs and in additional therapeutic areas. And with a larger base of operations, we will be able to create synergies that will reduce costs, and leverage on the respective expertise and experience to better serve the medical community," he said.
Pfizer's worldwide portfolio of innovative medicines spans diseases as diverse as cancer, epilepsy, depression, and high blood pressures, and includes 14 medicines that are number one in their therapeutic category. In Thailand, Pfizer has one of the deepest and broadest portfolios of medicines in the industry, with a strong presence in cardiovascular, cholesterol lowering, central nervous system illness, infectious disease, and Erectile Dysfunction or ED.
The acquisition of Pharmacia will expand Pfizer Thailand's offering of medicines into oncology and ophthalmology. In addition, it will expand Pfizer's share in the Cox-II market for the treatment of pain and arthritis, where the two companies have been jointly promoting products.
"We will use the depth of experience we have at Pfizer and Pharmacia to further strengthen the position of the Pharmacia products in Thailand in terms of support we can provide to the patients and the medical community at large," Mr. Naj said.
"That is what being bigger in the pharmaceutical industry delivers," he said, citing the fact that research and development require enormous investments today, while at the same time there is a lot of pressure to contain health care costs. "We are able to meet these challenges by Pfizer joining hands with resourceful companies, such as Pharmacia."
He said that Pfizer in 2002 spent $5.3 billion in R&D, and the integration of Pharmacia will significantly enhance Pfizer's ability to turn scientific advances into products that both extend lives and improve the quality of life for patients worldwide. Pfizer will have 400 new projects in its discovery pipeline, and will have the world's largest privately-funded biomedical company in the world. "Many of these new discoveries will potentially be available for Thailand in the future," said Mr. Naj.
"In Thailand, the large base of operations will allow us to devote more resources to philanthropic and other activities aimed at supporting education in science and health care, and partnering with government agencies and medical communities in supporting their work for the patient," he said. "In the past we have undertaken some of these activities, mostly through our non-profit Pfizer Thailand Foundation. As a larger company, we will be able to do more in Thailand. The acquisition of Pharmacia enhances Pfizer's commitment."
For more information, please contact :
Pongprach Surojnametakul
Boodsaba Sookabat
PR & Associates Ltd.
Tel. 0-2651-8989 ext. 330, 222
Fax 0-2651-9649-50
e-mail : [email protected]
Contact:
Warut Watanakun
02-665-4580 (O)
01-825-0361 (M) End.
-SN-